289 related articles for article (PubMed ID: 33983906)
1. Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia.
Tejedor JR; Bueno C; Vinyoles M; Petazzi P; Agraz-Doblas A; Cobo I; Torres-Ruiz R; Bayón GF; Pérez RF; López-Tamargo S; Gutierrez-Agüera F; Santamarina-Ojeda P; Ramírez-Orellana M; Bardini M; Cazzaniga G; Ballerini P; Schneider P; Stam RW; Varela I; Fraga MF; Fernández AF; Menéndez P
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 33983906
[TBL] [Abstract][Full Text] [Related]
2. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.
Geng H; Brennan S; Milne TA; Chen WY; Li Y; Hurtz C; Kweon SM; Zickl L; Shojaee S; Neuberg D; Huang C; Biswas D; Xin Y; Racevskis J; Ketterling RP; Luger SM; Lazarus H; Tallman MS; Rowe JM; Litzow MR; Guzman ML; Allis CD; Roeder RG; Müschen M; Paietta E; Elemento O; Melnick AM
Cancer Discov; 2012 Nov; 2(11):1004-23. PubMed ID: 23107779
[TBL] [Abstract][Full Text] [Related]
3. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia.
Lopez-Millan B; Sanchéz-Martínez D; Roca-Ho H; Gutiérrez-Agüera F; Molina O; Diaz de la Guardia R; Torres-Ruiz R; Fuster JL; Ballerini P; Suessbier U; Nombela-Arrieta C; Bueno C; Menéndez P
Leukemia; 2019 Jul; 33(7):1557-1569. PubMed ID: 30635633
[TBL] [Abstract][Full Text] [Related]
4. Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis.
Agraz-Doblas A; Bueno C; Bashford-Rogers R; Roy A; Schneider P; Bardini M; Ballerini P; Cazzaniga G; Moreno T; Revilla C; Gut M; Valsecchi MG; Roberts I; Pieters R; De Lorenzo P; Varela I; Menendez P; Stam RW
Haematologica; 2019 Jun; 104(6):1176-1188. PubMed ID: 30679323
[TBL] [Abstract][Full Text] [Related]
5. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
[TBL] [Abstract][Full Text] [Related]
6. Integration of high-resolution methylome and transcriptome analyses to dissect epigenomic changes in childhood acute lymphoblastic leukemia.
Busche S; Ge B; Vidal R; Spinella JF; Saillour V; Richer C; Healy J; Chen SH; Droit A; Sinnett D; Pastinen T
Cancer Res; 2013 Jul; 73(14):4323-36. PubMed ID: 23722552
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation profiling of pediatric B-cell lymphoblastic leukemia with KMT2A rearrangement identifies hypomethylation at enhancer sites.
Bergmann AK; Castellano G; Alten J; Ammerpohl O; Kolarova J; Nordlund J; Martin-Subero JI; Schrappe M; Siebert R
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27786413
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
9. MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.
Juszczynski P; Rodig SJ; Ouyang J; O'Donnell E; Takeyama K; Mlynarski W; Mycko K; Szczepanski T; Gaworczyk A; Krivtsov A; Faber J; Sinha AU; Rabinovich GA; Armstrong SA; Kutok JL; Shipp MA
Clin Cancer Res; 2010 Apr; 16(7):2122-30. PubMed ID: 20332322
[TBL] [Abstract][Full Text] [Related]
10. Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency.
Muñoz-López A; Romero-Moya D; Prieto C; Ramos-Mejía V; Agraz-Doblas A; Varela I; Buschbeck M; Palau A; Carvajal-Vergara X; Giorgetti A; Ford A; Lako M; Granada I; Ruiz-Xivillé N; Rodríguez-Perales S; Torres-Ruíz R; Stam RW; Fuster JL; Fraga MF; Nakanishi M; Cazzaniga G; Bardini M; Cobo I; Bayon GF; Fernandez AF; Bueno C; Menendez P
Stem Cell Reports; 2016 Oct; 7(4):602-618. PubMed ID: 27666791
[TBL] [Abstract][Full Text] [Related]
11. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation.
Ferrando AA; Armstrong SA; Neuberg DS; Sallan SE; Silverman LB; Korsmeyer SJ; Look AT
Blood; 2003 Jul; 102(1):262-8. PubMed ID: 12637319
[TBL] [Abstract][Full Text] [Related]
12. Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia.
Sanjuan-Pla A; Bueno C; Prieto C; Acha P; Stam RW; Marschalek R; Menéndez P
Blood; 2015 Dec; 126(25):2676-85. PubMed ID: 26463423
[TBL] [Abstract][Full Text] [Related]
13. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options.
Stumpel DJ; Schneider P; van Roon EH; Boer JM; de Lorenzo P; Valsecchi MG; de Menezes RX; Pieters R; Stam RW
Blood; 2009 Dec; 114(27):5490-8. PubMed ID: 19855078
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants.
Stam RW; Schneider P; Hagelstein JA; van der Linden MH; Stumpel DJ; de Menezes RX; de Lorenzo P; Valsecchi MG; Pieters R
Blood; 2010 Apr; 115(14):2835-44. PubMed ID: 20032505
[TBL] [Abstract][Full Text] [Related]
15. A distinct set of long non-coding RNAs in childhood MLL-rearranged acute lymphoblastic leukemia: biology and epigenetic target.
Fang K; Han BW; Chen ZH; Lin KY; Zeng CW; Li XJ; Li JH; Luo XQ; Chen YQ
Hum Mol Genet; 2014 Jun; 23(12):3278-88. PubMed ID: 24488769
[TBL] [Abstract][Full Text] [Related]
16. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
17. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.
Benito JM; Godfrey L; Kojima K; Hogdal L; Wunderlich M; Geng H; Marzo I; Harutyunyan KG; Golfman L; North P; Kerry J; Ballabio E; Chonghaile TN; Gonzalo O; Qiu Y; Jeremias I; Debose L; O'Brien E; Ma H; Zhou P; Jacamo R; Park E; Coombes KR; Zhang N; Thomas DA; O'Brien S; Kantarjian HM; Leverson JD; Kornblau SM; Andreeff M; Müschen M; Zweidler-McKay PA; Mulloy JC; Letai A; Milne TA; Konopleva M
Cell Rep; 2015 Dec; 13(12):2715-27. PubMed ID: 26711339
[TBL] [Abstract][Full Text] [Related]
18. H3K79 methylation profiles define murine and human MLL-AF4 leukemias.
Krivtsov AV; Feng Z; Lemieux ME; Faber J; Vempati S; Sinha AU; Xia X; Jesneck J; Bracken AP; Silverman LB; Kutok JL; Kung AL; Armstrong SA
Cancer Cell; 2008 Nov; 14(5):355-68. PubMed ID: 18977325
[TBL] [Abstract][Full Text] [Related]
19. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.
Stam RW; den Boer ML; Passier MM; Janka-Schaub GE; Sallan SE; Armstrong SA; Pieters R
Leukemia; 2006 Feb; 20(2):264-71. PubMed ID: 16357833
[TBL] [Abstract][Full Text] [Related]
20. Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.
Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB
Clin Cancer Res; 2015 Mar; 21(6):1395-405. PubMed ID: 25573381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
